Shots:

• Pharmapark to get exclusive rights to commercialize HD204 and is responsible for local registration- sales- and marketing of the biosimilar in Russia in collaboration with Russian import substitution strategy
• Prestige BioPharma will be responsible for commercial supply the product out of its manufacturing facilities in Osong- Korea
• Prestige’s (HD204) is currently being evaluated in P-III SAMSON-II trial that involves assessing the safety & efficacy of HD204 to the reference- Roche’s Avastin for multiple cancer indications

  Ref: Business Wire | Image: Prestige Biopharma